Arvid Carlsson (25 January 1923 – 29 June 2018)[2][3][4] was a Swedish neuropharmacologist who is best known for his work with the neurotransmitter dopamine and its effects in Parkinson's disease.

For his work on dopamine, Carlsson was awarded the Nobel Prize in Physiology or Medicine in 2000, together with Eric Kandel and Paul Greengard.

[4][7] In 1944, he participated in the task of examining prisoners of Nazi concentration camps, whom Swedish aristocrat Folke Bernadotte had managed to bring to Sweden, which was neutral during World War II.

[5] Zimelidine was later withdrawn from the market due to rare cases of Guillain–Barré syndrome,[11] but Carlson's research paved the way for fluoxetine (Prozac), one of the most widely used prescription medicines in the world.

[7] Carlsson was still an active researcher and speaker when he was over 90 years old and, together with his daughter Lena, he worked[12] on OSU6162, a dopamine stabilizer which alleviates symptoms of post-stroke fatigue.

[13] Carlsson's research on the brain's chemical signals and the resulting treatment for Parkinson's disease earned him the 2000 Nobel Prize in Physiology or Medicine, which he shared with Paul Greengard and Eric R.